Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $1.1 billion.

  • Neurocrine Biosciences' Long-Term Investments rose 4374.58% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 4374.58%. This contributed to the annual value of $1.1 billion for FY2025, which is 4374.58% up from last year.
  • Neurocrine Biosciences' Long-Term Investments amounted to $1.1 billion in Q4 2025, which was up 4374.58% from $998.5 million recorded in Q3 2025.
  • Neurocrine Biosciences' Long-Term Investments' 5-year high stood at $1.1 billion during Q4 2025, with a 5-year trough of $244.6 million in Q1 2023.
  • Its 4-year average for Long-Term Investments is $620.2 million, with a median of $643.9 million in 2024.
  • In the last 5 years, Neurocrine Biosciences' Long-Term Investments soared by 580.75% in 2021 and then soared by 18634.51% in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Long-Term Investments stood at $513.7 million in 2021, then surged by 33.83% to $687.5 million in 2023, then grew by 7.56% to $739.5 million in 2024, then skyrocketed by 43.75% to $1.1 billion in 2025.
  • Its Long-Term Investments was $1.1 billion in Q4 2025, compared to $998.5 million in Q3 2025 and $873.8 million in Q2 2025.